Jaguar health enters exclusive crofelemer distribution and license agreement with quadri pharmaceuticals store for multiple target indications in middle east markets

Agreement grants quadri pharmaceuticals store exclusive promotional, commercialization, and distribution rights in bahrain, kuwait, qatar, saudi arabia, the united arab emirates, and oman for human indications of crofelemer approved in the u.s., including future target indications san francisco, ca / accesswire / march 31, 2022 / jaguar health, inc. (nasdaq:jagx) today announced that the company has entered an agreement (the "agreement") with quadri pharmaceuticals store llc (quadri pharma) that grants quadri pharma exclusive promotional, commercialization, and distribution rights for specified human indications of crofelemer in bahrain, kuwait, qatar, saudi arabia, the united arab emirates (uae), and oman following regulatory approval to market crofelemer in these countries for the specified indications, including the indication currently approved in the u.s. for hiv-related diarrhea, and cancer therapy-related diarrhea, for which crofelemer is currently in a pivotal phase 3 clinical trial. in addition, the agreement grants quadri pharma exclusive rights to distribute crofelemer in these countries in the immediate future under named patient programs.
JAGX Ratings Summary
JAGX Quant Ranking